IMC Germany Announces Preliminary Q3, 2024 Showing A 50% Increase In Revenue Compared To Q2, Where IMC Germany Sold About CAD$ 3.5M

Author: Benzinga Newsdesk | October 02, 2024 08:11am

IM Cannabis Corp. (CSE:IMCC) (NASDAQ:IMCC) (the "Company", "IMCannabis", or "IMC"), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that the preliminary sales results in Germany by its German subsidiary, Adjupharm GmbH ("IMC Germany"), for the third quarter of 2024 have significantly exceeded expectations, showing a remarkable 50% increase in revenue compared to the second quarter, where IMC Germany sold about CAD$ 3.5M. This outstanding growth demonstrates IMC Germany's successful execution of its strategic initiatives and strong market demand for its products.

 

Posted In: CSE:IMCC IMCC